Hazem Koozi, Jonas Engström, Martin Spångfors, Hans Friberg, Attila Frigyesi
{"title":"血浆内司他丁是重症监护中急性肾损伤和肾脏替代疗法需求的早期肌酐独立预测因子","authors":"Hazem Koozi, Jonas Engström, Martin Spångfors, Hans Friberg, Attila Frigyesi","doi":"10.1101/2024.04.25.24306345","DOIUrl":null,"url":null,"abstract":"<strong>Purpose</strong> Endostatin is a promising biomarker for predicting acute kidney injury (AKI) and mortality in the intensive care unit (ICU). We investigated plasma endostatin upon ICU admission as a predictor of AKI, renal replacement therapy (RRT), and 30-day mortality.","PeriodicalId":501249,"journal":{"name":"medRxiv - Intensive Care and Critical Care Medicine","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plasma endostatin is an early creatinine independent predictor of acute kidney injury and need for renal replacement therapy in critical care\",\"authors\":\"Hazem Koozi, Jonas Engström, Martin Spångfors, Hans Friberg, Attila Frigyesi\",\"doi\":\"10.1101/2024.04.25.24306345\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Purpose</strong> Endostatin is a promising biomarker for predicting acute kidney injury (AKI) and mortality in the intensive care unit (ICU). We investigated plasma endostatin upon ICU admission as a predictor of AKI, renal replacement therapy (RRT), and 30-day mortality.\",\"PeriodicalId\":501249,\"journal\":{\"name\":\"medRxiv - Intensive Care and Critical Care Medicine\",\"volume\":\"21 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Intensive Care and Critical Care Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.04.25.24306345\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Intensive Care and Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.04.25.24306345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Plasma endostatin is an early creatinine independent predictor of acute kidney injury and need for renal replacement therapy in critical care
Purpose Endostatin is a promising biomarker for predicting acute kidney injury (AKI) and mortality in the intensive care unit (ICU). We investigated plasma endostatin upon ICU admission as a predictor of AKI, renal replacement therapy (RRT), and 30-day mortality.